Key Drivers
- Strong Liquidity
- Weak Margins
- Ongoing Cash Burn
AIAI Summary
LEGN is shifting from a pure CARVYKTI trade to a platform story, but the investment case still hinges on CARVYKTI staying strong enough to fund early pipeline optionality like LB2501 while avoiding further dilution, margin pressure, or a growth slowdown that would force a de-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Weak Margins
- •Ongoing Cash Burn
LEGN has a solid liquidity cushion with cash above debt, but persistent losses, margin pressure, and negative cash flow show it still has to prove it can turn revenue scale into durable profitability.
Price Behavior
Key Price Behavior Insights:
- •Base forming
- •Resistance cap
- •Breakdown hold
LEGN remains in a fragile recovery last month after a sharp breakdown, with support near $27.9-$28.4 holding but resistance at $33.5-$36.3 still limiting any trend reversal.
Sharp breakdown on 2026-06-18 to a 21-day low near the high-20s
Sentiment & News
Key News Insights:
- •Early efficacy
- •Clean safety
- •Dilutive financing
Legend Biotech reported encouraging early proof-of-concept data for LB2501, but the positive clinical momentum was tempered by a $226 million ADS offering that could weigh on shares near term.
The pipeline update is constructive for long-term value, but the new share offering likely creates a short-term overhang on the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings